Skip to main content
. Author manuscript; available in PMC: 2014 May 21.
Published in final edited form as: Curr Oncol Rep. 2009 May;11(3):193–199. doi: 10.1007/s11912-009-0028-0

Figure 1.

Figure 1

A–C, Selected ongoing randomized trials of novel antitumor therapies in neuroendocrine tumors. IFN—interferon; IV—intravenously; LAR—long-acting release; PFS—progression-free survival; PO—orally; RADIANT—An Open Label, Stratified, Single-Arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy; SC—subcutaneously.